Marksans Pharma Ltd Q2FY18
Consolidated Results Q2FY18: (Rs. in crore)
|EBITDA Margin (%)||11.5||825|
|Net Profit (adjusted)||10.4||1,286.7|
Marksans Pharma Ltd consolidated revenue for the quarter came in at Rs. 273.8 crore, registering 51.8% yoy increase.
EBITDA for the quarter rose by 441.4% yoy to Rs. 31.4 crore with a corresponding margin expansion of 825 bps. EBITDA margin for the quarter stood at 11.5%. This margin expansion was aided by favourable movements in inventories.
The PAT for the quarter came in at Rs. 10.4 crore, yoy increase of 1286.7%.
Marksans Pharma Ltd is currently trading at Rs. 49.10, up by 0.15 points or 0.31% from its previous closing of Rs. 48.95 on the BSE.
The scrip opened at Rs. 49.70 and has touched a high and low of Rs. 50.90 and Rs. 48.40 respectively. So far 1,46,16,073(NSE+BSE) shares were traded on the counter. The stock is currently trading below its 200 DMA.